# Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

> **NCT07748364** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Joshua Brody** · enrollment: 16 (estimated)

## Conditions studied

- Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Relapsed/Refractory Mantle Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Glofitamab

## Key facts

- **NCT ID:** NCT07748364
- **Lead sponsor:** Joshua Brody
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748364, "Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07748364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*